Opus Genetics
IRD
49 hedge funds and large institutions have $16M invested in Opus Genetics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 10 closing their positions.
3,833% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $36K
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
23% more capital invested
Capital invested by funds: $13M → $16M (+$2.99M)
20% more funds holding
Funds holding: 41 → 49 (+8)
0.93% more ownership
Funds ownership: 16.61% → 17.55% (+0.93%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$234K |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$191K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$186K |
| 4 |
Squarepoint
New York
|
+$165K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$429K |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$130K |
| 3 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$73.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$70K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$65.4K |
IRD Hedge Fund Activity: Q2 2023 in Review
49 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2023, worth a combined $16M — up 23% from $13M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IRD positions and 10 closed out — a net gain of 8 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $234K. The largest seller was Renaissance Technologies, cutting an estimated $429K.
- 49 institutional investors held Opus Genetics (IRD) as of Q2 2023, up from 41 in Q1 2023.
- Funds reported $16M of Opus Genetics stock for Q2 2023, up 23% quarter-over-quarter.
- 18 funds opened new Opus Genetics positions in Q2 2023 and 10 closed out, a net change of +8 holders.
- The largest Opus Genetics buyer in Q2 2023 was Stratos Wealth Partners, an estimated $234K added.
- The largest Opus Genetics seller in Q2 2023 was Renaissance Technologies, an estimated $429K sold.
Based on aggregated 13F filings for Q2 2023.